A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis

Study Overview
=================
Brief Summary
-----------------
The purpose of this trial is to compare the anti-psoriatic effect of eight different formulations of vitamin D analogues using a psoriasis plaque test design

Conditions
-----------------
Psoriasis Vulgaris

Intervention / Treatment
-----------------
* Drug: Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects having understood and signed an informed consent form. Either sex Age 18 years or above All skin types and any ethnic origin Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or trunk. Exclusion Criteria: Females who are pregnant, or who wish to become pregnant during the study, or who are breast feeding Systemic treatment with biological therapies (marketed or not marketed) with a possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 half-lives (which-ever is longer) for experimental biological products prior to randomisation Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids, immuno-suppressants) within the 4-week period prior to randomisation Subjects using one of the following topical drugs for the treatment of psoriasis within the 4 week period prior to randomisation and during the study: Potent or very potent (WHO group III-IV) corticosteroids PUVA or Grenz ray therapy Subjects using one of the following topical drugs for the treatment of psoriasis within two weeks prior to randomisation and during the study: WHO group I-II corticosteroids (except if used for treatment of scalp psoriasis) Topical retinoids Vitamin D analogues Topical immunomodulators (e.g. macrolides) Anthracen derivatives Tar Salicylic acid UVB therapy Subjects known to be non-responder to topical vitamin D analogues (e.g., known history of no improvement or worsening of psoriasis with e.g., calcipotriol, calcitriol or tacalcitol when used according to current SmPc) Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the 4 week period prior to randomisation or longer, if the class of the substance requires a longer washout as defined above (e.g., biological treatments) Subjects with current participation in any other interventional clinical, based on interview of the subject Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis Subjects with known or suspected hypersensitivity to component(s) of the investigational products Subjects with known/suspected disorders of calcium metabolism associated with hypercalcaemia Subjects with known severe hepatic and/or severe renal insufficiency Subjects with any concomitant medical or dermatological disorder(s) which might preclude accurate evaluation of the psoriasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Calcipotriol ointment<br> | Drug: Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues<br>* Once daily application<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total Clinical Score of clinical symptoms |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical scores, lesions thickness |  | 4 weeks |